Navigation Links
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:5/21/2013

sing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen R&D Ireland is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen R&D Ireland, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; impact of business combinations; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for th
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
2. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
3. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
4. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
5. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
6. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
7. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
8. GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014   Hospira, Inc. (NYSE: ... and infusion technologies, today announced that the company will ... on Wednesday, Jan. 14, 2015, in San Francisco.  ... at 10:30 a.m. Pacific time on Wednesday, Jan. 14, ... through a live audiocast accessible via the Investor Relations ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ( ... of equipment for the testing of marijuana potency ... the new Luminary™ Profiler, the industry,s first product ... in a cost-effective, portable unit. Designed ... needs of the cannabis industry, the Luminary™ Profiler ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... Pa., June 25, 2007 /PRNewswire-FirstCall/ --,Genaera Corporation ... of trodusquemine (MSI-1436) for the treatment of ... (ADA) 67th,Scientific Sessions, June 22-25 in Chicago, ... lead author of Abstract #1801-P,presented, "Trodusquemine is ...
... blood sugar reductions seen across range of,patient populations, ... high risk of developing diabetes , * Galvus ... efficacy in combination with commonly used diabetes,medicines , ... studies showing,incidence of side effects similar to placebo ...
Cached Medicine Technology:Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 2Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 3Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 2New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 3New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 5New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 6
(Date:12/21/2014)... California (PRWEB) December 21, 2014 Serious ... search for Vintage 1967 Jm Morrison and the Doors International ... posters. This would also be the only time that ... concert was on Nov. 25, 1967. According to Hawley, ... D.C. They did play the Alexandria Roller Rink earlier ...
(Date:12/21/2014)... 2014 Theme and plugin ... intro plugin for Final Cut Pro X entitled ProMotion. ... and more with absolute ease.” Said Christiana Austin, CEO ... tools needed to easily animate their media inside FCPX.” ... X users to animate pictures, videos, logos, and more ...
(Date:12/21/2014)... 2014 Concept Plus, LLC. a SDB ... in Fairfax, VA., today announced it has been recognized ... list, which ranks the fastest growing government contracting small businesses ... 2013. , This is the first year that Concept Plus, ... 20 with a 95.92% compound annual growth rate. “For Concept ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of sweet ... occasion dresses for the coming new year. , ... for global women. Now, all the models on its ... off. Among the new items, the model of 10986064 ... very popular. What’s more, Weddingshe.com also provides a fast ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The print ... Post, with a distribution of approximately 160,000 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2
... Eularis, will be delivering a MasterClass on how to tell if you are making ... WHAT: MasterClass on the latest techniques, strategies and analysis, ... measure financial impact of sales, ... WHERE: 1 Northumberland Avenue, Trafalgar Square. London, , ...
... economic conditions and the unknown effect of healthcare ... Milliman, Inc., one of the premier global ... total medical spending for its "typical American family ... While cost trends are decelerating for the third-straight ...
... Calif., May 18 Fate Therapeutics, Inc. ... the Company,s executive team with the addition of Pratik ... With more than a decade of clinical development ... trials of Stem Cell Modulators (SCMs), small molecules and ...
... show promise for better protection against flu , , MONDAY, ... virus-like particles (VLPs) could provide stronger and longer-lasting protection ... Even better, VLP vaccines, which can be grown in ... twice as quickly as conventional vaccines, according to research ...
... about vaginal dryness and pain and are reluctant to ... international survey presented today at the European Congress on ... over a third (39 percent) of post-menopausal women experience ... women who have recently experienced vaginal dryness and pain ...
... in Clinical Trials and Population Health MonitoringLINCOLN, R.I., May 18 ... well-being as a good night,s sleep. Yet millions of us ... -- suffer from chronic sleep problems or disorders. Every year, ... or insufficient sleep and disease. Now there is a simple, ...
Cached Medicine News:Health News:MEDIA ALERT - Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London 2Health News:Milliman Indicates 2009 Medical Cost for 'American family of four' Exceeds $16,700 Based on 7.4% Cost Increase 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 3Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 4Health News:New Methods Could Speed Production of Flu Vaccines 2Health News:7 out of 10 women too embarrassed to discuss vaginal dryness and pain with their physician 2Health News:QualityMetric Offers Way to Measure the Impact of Sleep Problems on Individuals and Groups 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: